From this statement in the abstract I believe Oncosec will have more than 5 patient data to report. More than 2 patients treated with Opdivo after ep-il12 will be a major plus if we see a few more responders to combo therapy. Since the abstract submission they would have had enough time to dose a few more patients in my opinion.
"At the time of abstract submission, 5 patients have completed all study-related procedures ... Two patients with treatment refractory TNBC received nivolumab ... and experienced clinically meaningful objective responses. Updated data will be presented."
News 
Market Data 
Discover 
AI
